X Facebook LinkedIn WhatsApp Press Releases Any 2024 2023 2022 2021 2020 2019 2018 (-) 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2017 September 24, 2017 argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis September 21, 2017 Invitation to the extraordinary shareholders’ meeting September 19, 2017 argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia August 23, 2017 argenx reports second quarter business update and half-year 2017 financial results August 22, 2017 argenx announces publication in Nature Medicine of preclinical data supporting the therapeutic potential of SIMPLE AntibodyTM ARGX-116 for the treatment of dyslipidemia August 16, 2017 argenx to host conference call & webcast to report second quarter business update and half year 2017 financial results on August 24, 2017 August 7, 2017 argenx to present at Wedbush PacGrow Healthcare Conference July 6, 2017 argenx presents full data from ARGX-111 Phase Ib study in patients with advanced cancers over-expressing the MET protein at Best of ASCO Asia 2017 (Singapore) June 19, 2017 argenx receives second preclinical milestone payment in collaboration with LEO Pharma June 13, 2017 argenx presents update on Phase I data from ARGX-110 expansion study in patients with cutaneous T-cell lymphomas at the International Conference of Malignant Lymphoma (ICML) June 12, 2017 argenx to Present at JMP Securities Life Sciences Conference May 22, 2017 argenx announces closing of NASDAQ IPO Pagination First page « First Previous page ‹ Previous Page 1 Current page 2 Page 3 Page 4 Next page Next › Last page Last »